Skip to main content

Facilitated PCI in patients with ST-elevation myocardial infarction.

Publication ,  Journal Article
Ellis, SG; Tendera, M; de Belder, MA; van Boven, AJ; Widimsky, P; Janssens, L; Andersen, HR; Betriu, A; Savonitto, S; Adamus, J; Peruga, JZ ...
Published in: N Engl J Med
May 22, 2008

BACKGROUND: We hypothesized that percutaneous coronary intervention (PCI) preceded by early treatment with abciximab plus half-dose reteplase (combination-facilitated PCI) or with abciximab alone (abciximab-facilitated PCI) would improve outcomes in patients with acute ST-segment elevation myocardial infarction, as compared with abciximab administered immediately before the procedure (primary PCI). METHODS: In this international, double-blind, placebo-controlled study, we randomly assigned patients with ST-segment elevation myocardial infarction who presented 6 hours or less after the onset of symptoms to receive combination-facilitated PCI, abciximab-facilitated PCI, or primary PCI. All patients received unfractionated heparin or enoxaparin before PCI and a 12-hour infusion of abciximab after PCI. The primary end point was the composite of death from all causes, ventricular fibrillation occurring more than 48 hours after randomization, cardiogenic shock, and congestive heart failure during the first 90 days after randomization. RESULTS: A total of 2452 patients were randomly assigned to a treatment group. Significantly more patients had early ST-segment resolution with combination-facilitated PCI (43.9%) than with abciximab-facilitated PCI (33.1%) or primary PCI (31.0%; P=0.01 and P=0.003, respectively). The primary end point occurred in 9.8%, 10.5%, and 10.7% of the patients in the combination-facilitated PCI group, abciximab-facilitated PCI group, and primary-PCI group, respectively (P=0.55); 90-day mortality rates were 5.2%, 5.5%, and 4.5%, respectively (P=0.49). CONCLUSIONS: Neither facilitation of PCI with reteplase plus abciximab nor facilitation with abciximab alone significantly improved the clinical outcomes, as compared with abciximab given at the time of PCI, in patients with ST-segment elevation myocardial infarction. (ClinicalTrials.gov number, NCT00046228 [ClinicalTrials.gov].)

Duke Scholars

Published In

N Engl J Med

DOI

EISSN

1533-4406

Publication Date

May 22, 2008

Volume

358

Issue

21

Start / End Page

2205 / 2217

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Tissue Plasminogen Activator
  • Time Factors
  • Recombinant Proteins
  • Myocardial Infarction
  • Male
  • Kaplan-Meier Estimate
  • Immunoglobulin Fab Fragments
  • Humans
  • Hemorrhage
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Ellis, S. G., Tendera, M., de Belder, M. A., van Boven, A. J., Widimsky, P., Janssens, L., … FINESSE Investigators. (2008). Facilitated PCI in patients with ST-elevation myocardial infarction. N Engl J Med, 358(21), 2205–2217. https://doi.org/10.1056/NEJMoa0706816
Ellis, Stephen G., Michal Tendera, Mark A. de Belder, Ad J. van Boven, Petr Widimsky, Luc Janssens, H. R. Andersen, et al. “Facilitated PCI in patients with ST-elevation myocardial infarction.N Engl J Med 358, no. 21 (May 22, 2008): 2205–17. https://doi.org/10.1056/NEJMoa0706816.
Ellis SG, Tendera M, de Belder MA, van Boven AJ, Widimsky P, Janssens L, et al. Facilitated PCI in patients with ST-elevation myocardial infarction. N Engl J Med. 2008 May 22;358(21):2205–17.
Ellis, Stephen G., et al. “Facilitated PCI in patients with ST-elevation myocardial infarction.N Engl J Med, vol. 358, no. 21, May 2008, pp. 2205–17. Pubmed, doi:10.1056/NEJMoa0706816.
Ellis SG, Tendera M, de Belder MA, van Boven AJ, Widimsky P, Janssens L, Andersen HR, Betriu A, Savonitto S, Adamus J, Peruga JZ, Kosmider M, Katz O, Neunteufl T, Jorgova J, Dorobantu M, Grinfeld L, Armstrong P, Brodie BR, Herrmann HC, Montalescot G, Neumann F-J, Effron MB, Barnathan ES, Topol EJ, FINESSE Investigators. Facilitated PCI in patients with ST-elevation myocardial infarction. N Engl J Med. 2008 May 22;358(21):2205–2217.

Published In

N Engl J Med

DOI

EISSN

1533-4406

Publication Date

May 22, 2008

Volume

358

Issue

21

Start / End Page

2205 / 2217

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Tissue Plasminogen Activator
  • Time Factors
  • Recombinant Proteins
  • Myocardial Infarction
  • Male
  • Kaplan-Meier Estimate
  • Immunoglobulin Fab Fragments
  • Humans
  • Hemorrhage